|

Plaque Reversal With Early, Aggressive Lipid Lowering Therapy

RECRUITINGSponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Actively Recruiting
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Started2022-07-07
Est. completion2026-12
Eligibility
Age18 Years – 50 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05783804

Summary

This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.

Eligibility

Age: 18 Years – 50 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosed with heterozygous familial hypercholesterolemia
* Adult between 18 and 50 years old
* LDL cholesterol levels above 100 mg/dl (\>2.6 mmol/L) at inclusion

Exclusion Criteria:

* Renal insufficiency, defined as eGFR \< 30 ml/min
* History of atherosclerotic cardiovascular events
* Atrial fibrillation
* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Conditions2

Coronary Artery Disease ProgressionHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.